-
Company Profile
Idera, Inc – Company Profile
Idera, Inc (Idera) is a software company. It provides B2B software tools such as data tools, application developer tools and DevOps tools. The company's data tools include IDERA, AquaFold, WhereScape, Uptime, Webyog, Qubole, BitTitan and Perspectium for database management, cross-platform database productivity and data warehouse automation, among others. Idera Developer Tools products include Embarcadero, Froala, Lansa, Lansa, Whole Tomato Software, Filestack, Yellowfin, FusionChart and UltraEdit for platform application development, design and deploy web applications and text editing, among others. The...
Add to Basket -
Company Profile
Aceragen Inc – Company Profile
Aceragen Inc (Acragen), formerly Idera Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company, which focuses on the discovery, strategic clinical development, and commercialization of therapeutic drug candidates for the treatment of cancer and rare diseases. It is developing ACG-801 and ACG-701. It intends to develop treatments for CF PEx and melioidosis through the development of ACG-701 and to treat Faber disease through the development of ACG-801. During FY2022, the company discontinued its development of tilsotolimod (IMO-2125). Aceragen is headquartered in Durham,...
Add to Basket -
Product Insights
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Products Market Report Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation...
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Drugs Market Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment includes...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC (malignancy) originates in the tissues of the lungs or the cells lining the airways. Symptoms usually occur in the later stages of the disease, and include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness, and unintentional weight...
-
Product Insights
Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gastrointestinal stromal tumors (GIST) belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. Its treatment involves the use of surgery, radiation therapy, targeted therapy, and chemotherapy. The Gastrointestinal Stromal Tumor pipeline market research report provides comprehensive information on the therapeutics under development for GIST, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Gene therapy for cancers
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Gene therapy for cancers segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – tilsotolimod sodium
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry tilsotolimod sodium Drug Details Tilsotolimod (IMO-2125) is under development for the treatment of various...
-
Product Insights
Chondrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chondrosarcoma is a cancer whose tumor cells produce pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, and changes in urination. Treatment includes chemotherapy and radiation therapy. The Chondrosarcoma pipeline drugs market research report provides comprehensive information on the therapeutics...
-
Sector Analysis
Gene Therapy Market Size, Share, Trends, Analysis and Forecast by Region, Segment, Oncology Therapy Type (Oncolytic Virotherapy, Gene Transfer, Gene Induced Immunotherapy) and End-user (Hospitals, Diagnostic Centers, Research Institutes), 2022–2027
The gene therapy in oncology market size was valued at US$ 2,045 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 23.7% during 2022-2027. The key to the growth has been the high prevalence of cancer and growing demand for gene therapy over conventional therapies. Additionally, key strategic partnerships and mergers and acquisitions are expected to accelerate market growth. Over the forecast period, the market will witness an increase in government support for...